Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus
Rhythm Pharmaceuticals shares were down 4.2% at $107.85 at 1:33 p.m. ET on Tuesday, after trading as low as $106.65.
AbbVie stock slips today as Fed minutes loom in thin year-end trade
AbbVie Inc. shares fell 0.8% to $228.89 in midday trading on Tuesday. The stock ranged between $228.66 and $231.55 after opening at $230.77, with volume near 795,000 shares.
Johnson & Johnson stock today: JNJ slips after $3.05B Halda cancer deal closes, Barclays lifts target
Johnson & Johnson shares edged lower on Tuesday after the company said it completed its $3.05 billion cash purchase of cancer-therapy developer Halda Therapeutics. The stock was down about 0.2% at $207.12 in midday trading. Executive vice president Jennifer Taubert called the closing a “strategic milestone” as J&J flagged about $0.20 of dilution to adjusted earnings per share — profit per share excluding certain one-time items — split between 2025 and 2026. Johnson & Johnson Investor Relations
Eli Lilly stock dips after report flags China price cuts for Mounjaro
Eli Lilly and Company shares were down $1.73, or about 0.2%, at $1,077.00 in morning trading on Tuesday.
Outlook Therapeutics stock jumps ahead of FDA’s Dec. 31 Lytenava decision
Outlook Therapeutics, Inc. shares closed Monday up 8.8% at $1.98 after trading between $1.78 and $1.98. The stock was last up about 2% at $2.02 in late after-hours trading, with about 5.7 million shares changing hands. StockAnalysis
BNAI stock doubles as Brand Engagement Network lands AI pharma deal, eyes recurring fees
Brand Engagement Network, Inc shares more than doubled on Monday after the company disclosed a project agreement to develop a custom AI engagement tool tied to an established prescription drug for a top-10 global pharmaceutical client. The company said it expects $250,000 in fourth-quarter development revenue and anticipates monthly license fees starting in the first quarter of 2026; the stock closed up 108.8% at $2.51. SEC+1
Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms
Novo Nordisk said it is lowering prices of its top-selling obesity drug Wegovy in China, after local outlet Yicai reported that list prices for the two highest doses were cut by 48% in the southwestern provinces of Yunnan and Sichuan. The new monthly list prices were 987 yuan and 1,284 yuan, Yicai said, citing local procurement authorities. Reuters
Gilead stock nudges up after Bernstein flags limited Medicaid pricing hit
Gilead Sciences shares were last up 0.15% at $124.91 on Monday, as investors weighed an analyst note that argued new Medicaid drug-pricing rules would have a limited financial impact on the company’s HIV franchise. Investing.com
Amgen stock slips to $330 as year-end pullback hits Wall Street; Fed minutes and MariTide updates in focus
Amgen shares fell 1% on Monday, ending the session down $3.30 at $329.63. StockAnalysis
Merck stock slips as 2025 winds down; MRK traders turn to Feb. 3 earnings next
Merck & Co shares eased on Monday, last trading down about 0.1% at $106.62 after ranging between $106.44 and $107.56. Trading volume was about 8.1 million shares.
JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next
Johnson & Johnson shares were last down 0.02% at $207.56 on Monday after the healthcare conglomerate said it completed its $3.05 billion cash acquisition of cancer drug developer Halda Therapeutics. The stock traded between $207.31 and $209.46, and J&J said it will account for the deal as a business combination and expects it to cut adjusted earnings per share by about $0.20, split evenly between the fourth quarter and 2026. JNJ.com
Pfizer stock slips after hours: what traders are watching ahead of Feb. 3 results
Pfizer Inc shares were down 0.3% at $25 in after-hours trading on Monday, after moving in a tight band during the regular session. The Health Care Select Sector SPDR Fund slipped and large-cap drugmakers traded mixed in late dealings.
Eli Lilly stock today: LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs
Shares of Eli Lilly and Company were up 0.2% at $1,078.73 in after-hours trading on Monday. The stock traded between $1,074.80 and $1,085.12 and about 1.64 million shares had changed hands.
Bristol Myers Squibb stock slips today as year-end trading thins and dividend date nears
Bristol Myers Squibb shares fell on Monday, with the drugmaker lagging a slightly weaker U.S. stock market in holiday-thinned trading. The stock was down 0.7% at $54.27 in afternoon trade.
Merck stock holds steady as year-end trading thins and Wall Street slips
Merck & Co shares were down 0.1% at $106.68 in midday trading on Monday, showing relative resilience as U.S. stocks drifted lower in thin year-end trade. The S&P 500-linked SPDR ETF fell 0.6% and the Nasdaq-100 tracker slid 0.7%.
Pfizer filings spotlight big portfolio shifts as Live Oak slashes stake 92%
Live Oak Private Wealth LLC cut its stake in Pfizer by 92.5% in the third quarter, selling 216,868 shares and ending the period with 17,627 shares, a regulatory filing showed. MarketBeat+2SEC+2
Merck stock holds near 52-week high as year-end trading turns to Fed minutes
Merck & Co shares finished the last U.S. session up 0.3% at $106.78, closing just below a 52-week high after a quiet, post-Christmas session left the broader market marginally lower. Yahoo Finance+1
Eli Lilly stock steadies into Monday as $55 million ABL Bio funding keeps pipeline in focus
Eli Lilly shares ended the holiday week little changed after South Korean biotech ABL Bio said it would receive $55 million in funding from the U.S. drugmaker under a research collaboration. PR Newswire
Johnson & Johnson stock (JNJ) holds near $208 as J&J halts eczema trial; what investors should watch before Monday’s open
Johnson & Johnson stock heads into the final trading week of 2025 with U.S. markets shut for the weekend and investors sorting through a fresh pipeline headline that surfaced late Friday. With the New York Stock Exchange closed today and the next regular session set for Monday, Dec. 29, attention is shifting to what could move JNJ when trading resumes—including biotech read-throughs, litigation headlines, and year-end macro catalysts in a holiday-shortened week. New York Stock Exchange+2Investopedia+2
Merck (MRK) Stock Today: Latest News, Analyst Forecasts, and What Investors Should Watch Before Monday’s Open
Merck & Co., Inc. heads into the final trading days of 2025 with shares hovering near fresh highs after a late-December climb that has put the pharmaceutical giant back in the spotlight for both defensive investors and catalyst-driven traders. With U.S. stock markets closed for the weekend, attention shifts to what could shape MRK when the regular session resumes Monday—ranging from year-end positioning and Fed expectations to analyst outlooks focused on Merck’s ability to grow beyond Keytruda. Reuters